Ps1071 Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-Cd74 Antibody Drug Conjugate (Adc), Stro-001, in Patients With Advanced B-Cell Malignancies

Abstract

favored A+CHP over CHOP. The median PFS was 48.2 months (95% CI: 35.2, not evaluable) versus 20.8 months (95% CI: 12.7, 47.6) for A+CHP and CHOP, respectively. The 3-year PFS was 57.1% (95% CI: 49.9, 63.7) for A+CHP compared with 44.4% (95% CI: 37.6, 50.9) for CHOP. Median OS was not reached for either arm. Adverse events (AEs), including incidence and severity of neutropenia and peripheral neuropathy, were similar between arms. AEs leading to death occurred in 7 patients (3%) in the A+CHP arm and 9 patients (4%) in the CHOP arm. Summary/Conclusion: Frontline treatment with A+CHP is superior to CHOP for patients with CD30-positive PTCL as demonstrated by a statistically significant improvement in PFS and OS, with a manageable safety profile.